POS0624 EFFICACY AND SAFETY OF LEVILIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS: PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL

• Published in: Annals of the rheumatic diseases Vol. 80; no. Suppl 1; pp. 550 - 551
• Main Authors: Mazurov, V., Korolev, M., Kundzer, A., Soroka, N., Kastanayan, A., Povarova, T., Plaksina, T., Antipova, O., Kretchikova, D., Smakotina, S., Tciupa, O., Raskina, T., Kropotina, T., Nesmeyanova, O., Popova, T., Dokukina, E., Plotnikova, A., Lutskii, A., Zinkina-Orihan, A.
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier B.V 01.06.2021; Elsevier Limited
• Subjects: Adverse events; Bilirubin; Blood; Cell number; Cholesterol; Clinical trials; Double-blind studies; Interleukin 6; Interleukin 6 receptors; Joint diseases; Lymphocytes; Methotrexate; Placebos; Rheumatoid arthritis; Safety; Triglycerides; Tuberculosis

Previously, the results of phase II AURORA clinical study of levilimab in subjects with active rheumatoid arthritis (RA) have been reported1. Here we report topline 24-weeks results of preliminary primary efficacy and safety analysis of phase 3 double-blind, placebo-controlled randomized clinical st...